Urinary biomarkers analysis as a diagnostic tool for early detection of pancreatic adenocarcinoma: Molecular quantification approach

Bibliographic Information
Authors: Samir S.; El-Ashry M.; Soliman W.; Hassan M.
Journal: Computational Biology and Chemistry
Publisher: Elsevier Ltd
Publication Date: 2024
Volume / Issue: Volume 112
Article No.: 108171
ISSN: 14769271
DOI: 10.1016/j.compbiolchem.2024.108171
Scopus: View on Scopus
PubMed: 39159599
Document Type: Article
Authors and Affiliations
Samir S., Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt; El-Ashry M., Surgery Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Soliman W., Gastroenterology and Hepatology Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Hassan M., Immunology Department, Theodor Bilharz Research Institute, Giza, 12411, Egypt
Abstract
Background and aims: Pancreatic ductal adenocarcinoma (PDAC) is infrequent. Currently, non-invasive biomarkers for early detection of PDAC are not accessible. Here, we intended to identify a set of urine markers able to discriminate patients with early-stage PDAC from healthy individuals. Patients and methods: Seventy-five urine samples from PDAC patients and 50 healthy controls were assayed using quantitative real-time PCR (qPCR). The chosen biomarkers were lymphatic vessel endothelial HA receptor (LYVE-1), regenerating islet-derived 1 alpha (REG1A), and trefoil factor family (TFF1). Results: LYVE-1, REG1A, and TFF1 expression in PDAC proved to be significantly elevated compared to healthy individuals (p < 0.05). Determination of these markers' expression might be useful for early tumor diagnosis with a sensitivity of 96 %, 100 %, and 73.33 % respectively, and a specificity of 100 %, 82 %, and 100 % respectively. Conclusion: We have recognized three diagnostic biomarkers REG1A, TFF1, and LYVE1 that can detect patients with early-stage pancreatic cancer in non-invasive urine specimens with improved sensitivity and specificity. To the best of our knowledge, there have been no prior investigations examining the mRNA expression levels of them in urine within the Egyptian population. © 2024 Elsevier Ltd
Keywords
Diagnostic Biomarkers; LYVE1; Pancreatic Ductal Adenocarcinoma; REG1A; TFF1; Urine; Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Early Detection of Cancer; Female; Humans; Lithostathine; Male; Middle Aged; Pancreatic Neoplasms; Trefoil Factor-1; Vesicular Transport Proteins; Biomarkers; Diagnosis; Endothelial cells; LYVE1 protein, human; REG1A protein, human; TFF1 protein, human; trefoil factor 1; tumor marker; vesicular transport protein; Diagnostics tools; Ductal adenocarcinomas; Healthy individuals; Regenerating islet-derived 1 alpha; Urinary biomarkers; early cancer diagnosis; genetics; human; pancreas tumor; pancreatic ductal carcinoma; Body fluids
Citation Information
Scopus Citations: 11
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
